Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Scientific Focus and Experimental Value The scientific value of the KLOW product lies in its ability to bring together multiple peptide systems within a single preparation
Tirzepatide (Mounjaro), the dual GIP/GLP-1 receptor agonist, is licensed by the MHRA for the treatment of type 2 diabetes
Researchers are designing new peptides that interact with multiple hormone receptors, using machine learning to predict activity, and following long-term experimental outcomes to assess sustained effects and minimize risk
TZDs improve peripheral insulin sensitivity
Featuring 94% sequence homology to endogenous human GLP-1, this 31-amino acid polypeptide incorporates two critical structural modifications: an aminoisobutyric acid (Aib) substitution at position 8 to prevent degradation by the DPP-4 enzyme, and the attachment of a C18 fatty diacid via a hydrophilic spacer
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
